#1 Clinical Trials Search in Europe

Sultiame

Sultiame, also known as Ospolot, is a medication that has been the subject of several clinical trials investigating its efficacy in treating various conditions. These trials have primarily focused on its use in childhood epilepsy syndromes and, more recently, in obstructive sleep apnea (OSA) in adults. Researchers are exploring different doses, formulations, and applications of Sultiame to better understand its potential benefits and side effects in these medical conditions.

Table of Contents

What is Sulthiame?

Sulthiame, also known by its brand name Ospolot, is a medication that has been used since the 1960s in several countries, including Germany, Austria, Switzerland, Israel, Australia, and Japan[1]. It is primarily used as an antiepileptic drug, which means it helps control seizures in people with epilepsy. Sulthiame has gained particular importance in treating certain types of childhood epilepsy.

Medical Conditions Treated with Sulthiame

Sulthiame is used to treat several medical conditions:

  • Childhood Epilepsy Syndromes: Sulthiame has become the first-choice treatment for benign focal epilepsies of childhood in some countries[1]. It is particularly effective in treating a condition called Benign Epilepsy with Centro-Temporal Spikes (BECTS), also known as Rolandic epilepsy[2].
  • Obstructive Sleep Apnea (OSA): Recent clinical trials are exploring the use of Sulthiame in treating moderate to severe obstructive sleep apnea in adults[3].

How Sulthiame Works

Sulthiame works by inhibiting an enzyme called carbonic anhydrase, particularly a subtype known as cytosolic hCA II. This inhibition leads to a slight increase in acidity inside cells, which is thought to stabilize neurons (brain cells) that might otherwise trigger seizures[1]. This mechanism helps explain its effectiveness in controlling epileptic seizures.

Current Clinical Trials

Several clinical trials are currently underway to further explore the uses and effects of Sulthiame:

  1. Obstructive Sleep Apnea Study: A large-scale trial is evaluating the efficacy, safety, and tolerability of three different doses of Sulthiame (100 mg, 200 mg, and 300 mg) compared to a placebo in adults with moderate to severe obstructive sleep apnea[3].
  2. Pharmacokinetics Study: A small pilot study is investigating how Sulthiame is processed by the body (its pharmacokinetics) and its tolerability in healthy volunteers. This study aims to help design future clinical trials and develop new pediatric formulations[1].
  3. EEG Effects in Childhood Epilepsy: A study is exploring how quickly Sulthiame affects brain activity (measured by EEG) in children with epilepsy syndromes that are activated during sleep[4].
  4. Comparison with Levetiracetam: A study is comparing the effectiveness of Sulthiame with another antiepileptic drug, Levetiracetam, in children with BECTS[2].

Dosage and Administration

Sulthiame is typically taken orally in the form of film-coated tablets. The dosage can vary depending on the condition being treated and the patient’s age:

  • For epilepsy in children, the dosage is determined by the treating physician based on the child’s specific needs[4].
  • In the obstructive sleep apnea trial, adults are being given once-daily doses of 100 mg, 200 mg, or 300 mg[3].
  • Currently available tablet strengths are 50 mg and 200 mg, which may not always allow for precise dosing in young children. Research is ongoing to develop more suitable pediatric formulations[1].

Potential Side Effects

As with all medications, Sulthiame can cause side effects. The ongoing clinical trials are closely monitoring for adverse events. Common side effects may include:

  • Gastrointestinal issues
  • Headache
  • Dizziness
  • Fatigue

It’s important to note that the full range of potential side effects is still being studied, particularly for its use in obstructive sleep apnea[3].

Comparisons with Other Medications

One ongoing study is directly comparing Sulthiame with Levetiracetam, another antiepileptic drug, for the treatment of BECTS in children. This study aims to determine if Levetiracetam is as effective as Sulthiame, which has been a standard treatment for this condition. The study is also comparing the safety, tolerability, cognitive effects, and impact on EEG patterns of these two medications[2].

Aspect Details
Conditions Studied Obstructive Sleep Apnea (OSA), Childhood Epilepsy Syndromes, Benign Epilepsy with Centro-Temporal Spikes (BECTS)
Dosages Tested 50 mg, 100 mg, 200 mg, 300 mg
Primary Outcomes Changes in AHI, Pharmacokinetic parameters, EEG improvements
Study Designs Randomized, double-blind, placebo-controlled; Open-label pharmacokinetic study; Exploratory EEG study
Safety Monitoring Adverse events, TEAEs, Serious TEAEs, Discontinuations due to adverse events
Potential Mechanisms Inhibition of carbonic anhydrase enzymes, Intracellular acidification

FAQ

  • What is Sultiame used for in clinical trials? Sultiame is being studied for its potential use in treating childhood epilepsy syndromes and obstructive sleep apnea (OSA) in adults. It has been used as a first-choice treatment for benign focal epilepsies of childhood in some countries.
  • How does Sultiame work? Sultiame is thought to work by inhibiting carbonic anhydrase enzymes, particularly cytosolic hCA II. This inhibition leads to intracellular acidification, which may help stabilize neurons that trigger seizures.
  • What are the different doses of Sultiame being tested? In the OSA trial, doses of 100 mg, 200 mg, and 300 mg are being tested. In the pharmacokinetics study, single doses of 50 mg, 100 mg, and 200 mg were administered to healthy volunteers.
  • What are the main outcomes being measured in these trials? The trials are measuring various outcomes, including changes in the apnea-hypopnea index (AHI) for OSA, pharmacokinetic parameters like elimination half-life and area under the curve (AUC), and improvements in sleep EEG patterns for childhood epilepsy syndromes.
  • Are there any side effects being monitored in these trials? Yes, the trials are monitoring for adverse events, treatment-emergent adverse events (TEAEs), serious TEAEs, and any events leading to discontinuation of the study drug. The overall safety and tolerability of Sultiame are being closely evaluated.

Ongoing Clinical Trials on Sultiame

  • Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone

    Not recruiting

    1 1
    Investigated drugs:
    Denmark Sweden

Glossary

  • Sultiame (Sulthiame): An antiepileptic medication that works by inhibiting carbonic anhydrase enzymes, used in the treatment of certain types of epilepsy and being studied for other conditions.
  • Obstructive Sleep Apnea (OSA): A sleep disorder characterized by repeated episodes of complete or partial obstruction of the upper airway during sleep, leading to pauses in breathing.
  • Apnea-Hypopnea Index (AHI): A measure used to assess the severity of sleep apnea, calculated by the number of apneas and hypopneas per hour of sleep.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Benign Epilepsy with Centro-Temporal Spikes (BECTS): A common childhood epilepsy syndrome characterized by seizures originating in the rolandic area of the brain.
  • Electroencephalogram (EEG): A test that records electrical activity in the brain, often used to diagnose and monitor epilepsy and sleep disorders.
  • Carbonic Anhydrase: An enzyme that catalyzes the conversion of carbon dioxide and water to bicarbonate and protons, playing a role in pH regulation.
  • Area Under Curve (AUC): A pharmacokinetic parameter that represents the total drug exposure over time.
  • Treatment-Emergent Adverse Event (TEAE): Any unfavorable and unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.
  • Interictal Epileptiform Activity: Abnormal electrical discharges in the brain that occur between seizures in people with epilepsy.

References

  1. https://clinicaltrials.gov/study/NCT03400189
  2. https://clinicaltrials.gov/study/NCT00471744
  3. https://clinicaltrials.gov/study/NCT05236842
  4. https://clinicaltrials.gov/study/NCT05885646